Navigating the Diagnostic Process and Lab Reports

Confirming a diagnosis of Pompe disease involves a carefully integrated sequence of specialized tests. Because the symptoms can overlap with many other muscle-wasting conditions, doctors use biochemical tests, genetic “blueprints,” and clinical symptoms together to ensure the diagnosis is accurate and to tailor the treatment plan ^[1][2].

The First Step: Enzyme Activity Testing

The diagnostic journey often begins with a screening test, such as a Dried Blood Spot (DBS). A small sample of blood is placed on a card and analyzed to measure the activity of the acid alpha-glucosidase (GAA) enzyme.

• The Signal: A low level of GAA activity is a “screening signal,” meaning the body may not be producing enough of the enzyme ^[1].
• The Follow-up: A DBS screening test is not a diagnosis on its own. A low result must always be confirmed by a secondary enzyme assay using leukocytes (white blood cells) or fibroblasts (skin cells) ^[3][4].

Confirming the Diagnosis: Integrating Genetics

While genetic testing is crucial, it is not the “only way” to diagnose Pompe disease. A confirmed diagnosis requires both deficient GAA enzyme activity in an appropriate assay AND compatible biallelic pathogenic GAA variants (mutations).

• Pathogenic Variants: Pompe is an autosomal-recessive condition. To have the disease, a person typically must inherit two disease-causing mutations—one from each parent ^[1].
• Variants of Uncertain Significance (VUS): Sometimes a genetic sequence reveals a variant that scientists aren’t sure causes disease. A VUS alone does not confirm Pompe disease, and genetic sequencing can sometimes miss structural or deep variants ^[3].
• Pseudodeficiency: Some people have a genetic variation called pseudodeficiency that makes their enzyme activity look low in a lab test, but they never actually develop the disease ^[5][6]. However, a pseudodeficiency variant can sometimes coexist with a true disease-causing variant. A specialist must reconcile the enzyme results, the genetic variants, and the clinical symptoms to confirm the diagnosis.

Understanding Autosomal-Recessive Inheritance

Because Pompe is autosomal-recessive, parents of a child with Pompe disease are typically carriers. Carriers have one working copy of the gene and one non-working copy. They do not have the disease themselves, but they can pass the non-working gene on. Siblings of a person with Pompe disease have a 25% chance of having the disease, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier. A genetic counselor can help with family cascade testing and reproductive planning.

The CRIM Status: Vital for Infants

If a diagnosis of Infantile-Onset Pompe Disease (IOPD) is confirmed, an important step is determining the CRIM status (Cross-Reactive Immunologic Material).

• What it Measures: CRIM status predicts whether the patient produces any detectable endogenous (their own) GAA protein. This helps estimate the immune system’s risk of reacting negatively to treatment ^[7].
• CRIM-Positive: The body produces some GAA protein. The immune system may recognize this protein as “self” and is generally less likely to mount a severe attack against the medicine, though some CRIM-positive genotypes still carry substantial antibody risk ^[8][9].
• CRIM-Negative: The body produces no GAA protein at all. When treatment begins, the immune system is highly likely to see the medicine as a foreign invader and create antibodies that block the drug from working ^[7][10]. This status helps doctors plan appropriate immune-tolerance protocols.

Understanding Your Lab Biomarkers

Once treatment or monitoring begins, your medical team may track several “biomarkers.” It is important to know that these are supportive adjuncts, not definitive measures of your total disease burden. They can fluctuate and may even be normal despite clinically important disease. They should always be interpreted alongside physical exams and respiratory tests.

Diagnostic Completeness Checklist

When reviewing your or your child’s diagnostic report with a specialist, ensure these pieces of information have been addressed:

1. Confirmatory GAA Enzyme Activity: Measured in leukocytes or fibroblasts (not just a DBS screen) ^[1].
2. GAA Genetic Variants: The specific names and classification (e.g., pathogenic, VUS) of the variants found ^[17].
3. Variant Phase: Confirmation by a geneticist of whether the variants are on opposite copies of the gene ^[1].
4. CRIM Status (for IOPD): Estimated by genotype or confirmed by a Western blot test ^[7].